OPKO Health Inc (OQ:OPK)

Business Focus: Medical & Diagnostic Laboratories

Sector:  Healthcare Industry:  Healthcare Facilities & Services
See Regulatory Filings on SEC
Company Contact
Address: 4400 Biscayne Blvd.
MIAMI FL 33137
Tel: 1-310-6917100
Website: https://www.opko.com
IR: See website
Key People
Phillip Frost
Chairman of the Board, Chief Executive Officer
Elias A. Zerhouni
President, Vice Chairman of the Board
Jane H. Hsiao
Vice Chairman of the Board, Chief Technical Officer
Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Charles W. Bishop
Chief Executive Officer of OPKO Renal
Tony F. Cruz
Chief Executive Officer, Transition Therapeutics, Inc
Steven D. Rubin
Executive Vice President - Administration, Director
Gary J. Nabel
Chief Innovation Officer, Director
Business Overview
OPKO Health, Inc. is a healthcare company. The Company's segments include diagnostics and pharmaceuticals. The diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. The pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates laboratory divisions, such as BioReference Health, GenPath and GenPath. Its Pharmaceutical Business has one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including pharmaceutical compounds, Oxyntomodulin, Biologics, Factor VIIa-CTP and others. It also owns an active pharmaceutical ingredients manufacturer in Israel through its subsidiary FineTech Pharmaceutical, Ltd.
Financial Overview
For the nine months ended 30 September 2023, OPKO Health Inc revenues decreased 17% to $681.6M. Net loss decreased 50% to $122.4M. Revenues reflect Diagnostics segment decrease of 37% to $391.1M, United States segment decrease of 27% to $463M, Spain segment decrease of 5% to $16.4M. Lower net loss reflects Pharmaceutical segment income increase from $9M to $57.2M, Diagnostics segment loss decrease of 25% to $113.3M.
Employees: 4,196 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $885.13M as of Dec 31, 2023
Annual revenue (TTM): $866.93M as of Dec 31, 2023
EBITDA (TTM): -$40.61M as of Dec 31, 2023
Net annual income (TTM): -$207.61M as of Dec 31, 2023
Free cash flow (TTM): -$41.11M as of Dec 31, 2023
Net Debt Last Fiscal Year: $123.29M as of Dec 31, 2023
Shares outstanding: 773,056,533 as of Nov 1, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.